2046-2047 / 2351
•
One trial:
•
BSC (n=26) versus bleomycin (n=22) versus cisplatin (n=38) versus cisplatin
plus bleomycin (n=30).
•
The conclusions were
•
cisplatin improved survival compared with BSC by 10 weeks
•
cisplatin was better than bleomycin or methotrexate
•
cisplatin monotherapy (median survival: 160 days) was at least as
effective as the platinum-based combinations.
Randomized trials chemotherapy versus BSC
Campbell JB et al Acta Otolaryngol 1987
Morton et al Cancer Chemother Pharmacol.1985